Table 6

 Incidence of adverse and serious adverse events

Adverse event typeInfliximab (n = 13)Etanercept continue therapyEscape
Week 0–15Week 16–35Week 0–35Week 0–15(n = 14)Week 0–35(n = 5)Week 16–35(n = 6)
AE, adverse event; SAE, serious adverse event.
*AEs were reported in more than one patient.
Serious (SAE)n (% of patients)n (% of patients)
    Patients with ⩾1 SAE0 (0)1 (7.7)1 (7.7)2 (14.3)1 (20.0)0 (0)
        Gastrointestinal disorders0 (0)0 (0)0 (0)1 (7.1)1 (20.0)0 (0)
        Cardiac disorders0 (0)0 (0)0 (0)1 (7.1)0 (0)0 (0)
        Musculoskeletal and connective tissue disorders0 (0)1 (7.7)1 (7.7)0 (0)0 (0)0 (0)
        Nervous system disorders0 (0)0 (0)0 (0)1(7.1)0 (0)0 (0)
        Respiratory disorders0 (0)0 (0)0 (0)1 (7.1)0 (0)0 (0)
Adverse (AE)*
    Patients with ⩾1 AE7 (53.8)4 (30.8)11 (84.6)7 (50.0)2 (40.0)2 (33.3)
        Gastrointestinal disorders0 (0)0 (0)0 (0)3 (21.4)1 (20)0 (0)
        Musculoskeletal and connective tissue disorders2 (15.4)2 (15.4)4 (30.8)1 (7.1)0 (0)2 (33.3)
        Nervous system disorders1 (7.7)0 (0)1 (7.7)1 (7.1)0 (0)1 (16.7)
        Respiratory disorders1 (7.7)0 (0)1 (7.7)4 (28.6)0 (0)0 (0)
        Skin and subcutaneous disorders3 (23.1)2 (15.4)5 (38.5)1 (7.1)0 (0)0 (0)
        General disorders and site reactions0 (0)0 (0)0 (0)1 (7.1)1 (20.0)0 (0)